title: European Vaccine Initiative: lessons from developing malaria vaccines.
abstract: For over 10 years, the European Vaccine Initiative (EVI; European Malaria Vaccine Initiative until 2009) has contributed to the development of 24 malaria candidate vaccine antigens with 13 vaccine candidates being advanced into Phase I clinical trials, two of which have been transitioned for further clinical development in sub-Saharan Africa. Since its inception the EVI organization has operated as a funding agency, but with a clear service-oriented strategy. The scientific successes and difficulties encountered during these years and how these efforts have led to standardization and harmonization in vaccine development through large-scale European consortia are discussed. In the future, the EVI will remain instrumental in the pharmaceutical and clinical development of vaccines against 'diseases of poverty' with a continued focus on malaria. EVI will continue to focus on funding and managing preclinical evaluation up to Phase I/II clinical trials and strengthening the vaccine-development infrastructure in Europe, albeit with a global orientation.
authors.affiliation: European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Im Neuenheimer Feld 326-3. OG, 69120 Heidelberg, Germany.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Geels
authors.forename: Egeruan B
authors.initials: EB
authors.lastname: Imoukhuede
authors.forename: Nathalie
authors.initials: N
authors.lastname: Imbault
authors.forename: Harry
authors.initials: H
authors.lastname: van Schooten
authors.forename: Terry
authors.initials: T
authors.lastname: McWade
authors.forename: Marita
authors.initials: M
authors.lastname: Troye-Blomberg
authors.forename: Roland
authors.initials: R
authors.lastname: Dobbelaer
authors.forename: Alister G
authors.initials: AG
authors.lastname: Craig
authors.forename: Odile
authors.initials: O
authors.lastname: Leroy
mesh_terms: D000276:Adjuvants, Immunologic / Q000592:standards; D000956:Antigens, Viral / Q000276:immunology; D002986:Clinical Trials as Topic; D005060:Europe; D006801:Humans; D017589:Immunization Programs / Q000191:economics / Q000458:organization & administration; D007391:International Cooperation; D008288:Malaria / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D017780:Malaria Vaccines / Q000191:economics* / Q000276:immunology / Q000592:standards; D057170:Translational Research, Biomedical / Q000191:economics* / Q000458:organization & administration; D022223:Vaccines, Subunit / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D017780:Malaria Vaccines; D022223:Vaccines, Subunit